Safety Study of Transmyocardial Revascularization (TMR) With Bone Marrow Aspirate (BMAC) for Angina Reduction (PHOENIX)
A Prospective, Multicenter, Single Arm Study of Transmyocardial Revascularization (TMR) Plus Bone Marrow Aspirate Concentrated (BMAC) Using the Cardiogenesis PHOENIX Combination Handpiece Delivery System
Sponsor: Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
More terminations from Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
A NA clinical study on Angina, this trial is terminated or withdrawn. The trial is conducted by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc. and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated NA
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .